|
1.
|
|
8 p, 573.0 KB |
A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants
/
Earl, Julie (Red de Investigación Biomédica en Cáncer (CIBERONC)) ;
Galindo-Pumariño, Cristina (Red de Investigación Biomédica en Cáncer (CIBERONC)) ;
Encinas, J. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Barreto, E. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Castillo, M.E. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Pachón, V. (Red de Investigación Biomédica en Cáncer (CIBERONC)) ;
Ferreiro, R. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Rodríguez-Garrote, M. (Red de Investigación Biomédica en Cáncer (CIBERONC)) ;
González-Martínez, S. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Diaz, L.R. (Hospital 12 de Octubre (Madrid)) ;
Chirivella, Isabel (Hospital Clínic Universitaride València) ;
Rodriguez, M. (Hospital Teresa Herrera) ;
de Castro, E.M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
García-Seisdedos, D. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Muñoz, G. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Rosa, J.M.R. (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)) ;
Marquez, M. (Centro Nacional de Investigaciones Oncológicas) ;
Malats, Núria (Centro Nacional de Investigaciones Oncológicas) ;
Carrato, A. (Red de Investigación Biomédica en Cáncer (CIBERONC)) ;
Universitat Autònoma de Barcelona
The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is around 5% due to the fact that the majority of patients present with advanced disease that is treatment resistant. [...]
2020 -  10.1016/j.ebiom.2020.102675
EBioMedicine, Vol. 53 (march 2020) , p. 102675
|
|
|
2.
|
|
17 p, 2.8 MB |
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
/
Martínez Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Cristóbal, Helena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Gironella, Meritxell (Hospital Clínic i Provincial de Barcelona) ;
Barranco, Luis E (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Calafato, Domenico (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez-Parrado, Silvia (Centro Nacional de Investigaciones Oncológicas) ;
Earl, Julie (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Manero-Rupérez, Noemí (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Moreno Merino, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Morales, Albert (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Guerra, Carmen (Centro Nacional de Investigaciones Oncológicas) ;
Navarro, Pilar (Institut d'Investigacions Biomèdiques de Barcelona) ;
García de Frutos, Pablo (Institut d'Investigacions Biomèdiques de Barcelona)
Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. [...]
2021 - 10.1016/j.ebiom.2021.103797
EBioMedicine, Vol. 75 (december 2021)
|
|
|
3.
|
|
18 p, 6.6 MB |
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
/
López de Maturana, Evangelina (Centro de Investigación Biomédica en Red de Cáncer) ;
Rodríguez, Juan Antonio (Centre de Regulació Genòmica) ;
Alonso, Lola (Centro de Investigación Biomédica en Red de Cáncer) ;
Lao, Oscar (Centre de Regulació Genòmica) ;
Molina-Montes, Esther (Centro de Investigación Biomédica en Red de Cáncer) ;
Martín-Antoniano, Isabel Adoración (Centro de Investigación Biomédica en Red de Cáncer) ;
Gómez-Rubio, Paulina (Centro de Investigación Biomédica en Red de Cáncer) ;
Lawlor, Rita (University and Hospital Trust of Verona. ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics) ;
Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Hidalgo, Manuel (Weill Cornell Medicine) ;
Iglesias, Mar (Parc de Salut MAR de Barcelona) ;
Molero, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Löhr, Matthias (Gastrocentrum, Karolinska Institutet and University Hospital) ;
Michalski, Christopher (Martin-Luther-University Halle-WittenberHalle (Saale). Department of Visceral, Vascular and Endocrine Surgery) ;
Perea, José (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
O'Rorke, Michael (The University of Iowa. College of Public Health) ;
Barberà, Victor Manuel (Hospital General Universitario de Elche) ;
Tardón, Adonina (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Farré, Antoni (Institut d'Investigació Biomèdica Sant Pau) ;
Muñoz-Bellvís, Luís (Instituto de Investigación Biomédica de Salamanca) ;
Crnogorac-Jurcevic, Tanja (Queen Mary University of London. Barts Cancer Institute, Centre for Molecular Oncology) ;
Domínguez-Muñoz, Enrique (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Gress, Thomas (University Hospital of Giessen and Marburg (Alemanya)) ;
Greenhalf, William (University of Liverpool. Department of Molecular and Clinical Cancer Medicine) ;
Sharp, Linda (Newcastle University, Institute of Health & Society) ;
Arnes, Luís (Columbia University Medical Center. Department of Systems Biology) ;
Cecchini, Lluís (Parc de Salut MAR de Barcelona) ;
Balsells, Joaquim (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Costello, Eithne (University of Liverpool. Department of Molecular and Clinical Cancer Medicine) ;
Ilzarbe, Lucas (Parc de Salut MAR de Barcelona) ;
Kleeff, Jörg (Martin-Luther-University Halle-WittenberHalle (Saale). Department of Visceral, Vascular and Endocrine Surgery) ;
Kong, Bo (Technical University of Munich. Department of Surgery) ;
Márquez, Mirari (Centro de Investigación Biomédica en Red de Cáncer) ;
Mora Brugués, Josefina (Institut d'Investigació Biomèdica Sant Pau) ;
O'Driscoll, Damian (University College Cork. National Cancer Registry Ireland and HRB Clinical Research Facility) ;
Scarpa, Aldo (University and Hospital Trust of Verona. ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics) ;
Ye, Weimin (Karolinska Institutet (Estocolm, Suècia). Department of Medical Epidemiology and Biostatistics) ;
Yu, Jingru (Karolinska Institutet (Estocolm, Suècia). Department of Medical Epidemiology and Biostatistics) ;
García-Closas, Montserrat (Centro Nacional de Investigaciones Oncológicas) ;
Kogevinas, M.. (Hospital del Mar (Barcelona, Catalunya)) ;
Rothman, Nathaniel (Centro Nacional de Investigaciones Oncológicas) ;
Silverman, Debra T. (Centro Nacional de Investigaciones Oncológicas) ;
Albanes, Demetrius (Centro Nacional de Investigaciones Oncológicas) ;
Arslan, Alan A. (New York University School of Medicine. Department of Population Health) ;
Beane-Freeman, Laura (Centro Nacional de Investigaciones Oncológicas) ;
Bracci, Paige M. (University of California. Department of Epidemiology and Biostatistics) ;
Brennan, Paul (International Agency for Research on Cancer (IARC)) ;
Bueno-de-Mesquita, Bas (National Institute for Public Health and the Environment (RIVM). Deparment for Determinants of Chronic Diseases (DCD)) ;
Buring, Julie (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Canzian, Federico (German Cancer Research Center (DKFZ. Genomic Epidemiology Group) ;
Du, Margaret (Memorial Sloan Kettering Cancer Center) ;
Gallinger, Steven (Sinai Health System. Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute) ;
Gaziano, J. Michael (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Goodman, Phyllis J. (SWOG Statistical Center, Fred Hutchinson Cancer Research Center) ;
Gunter, Marc (International Agency for Research on Cancer (IARC)) ;
LeMarchand, Loic (University of Hawaii Cancer Center. Cancer Epidemiology Program) ;
Li, Donghui (University of Texas MD Anderson Cancer Center) ;
Neale, Rachael E. (QIMR Berghofer Medical Research Institute (Brisbane, Austràlia). Population Health Department) ;
Peters, Ulrika (Fred Hutchinson Cancer Research Center. Division of Public Health Sciences) ;
Petersen, Gloria M. (Mayo Clinic College of Medicine. Department of Health Sciences Research) ;
Risch, Harvey A. (Yale School of Public Health. Department of Chronic Disease Epidemiology) ;
Sánchez, Maria José (Universidad de Granada) ;
Shu, Xiao-Ou (Vanderbilt University School of Medicine. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center) ;
Thornquist, Mark D. (Fred Hutchinson Cancer Research Center. Division of Public Health Sciences) ;
Visvanathan, Kala (Mayo Clinic College of Medicine. Department of Health Sciences Research) ;
Zheng, Wei (Vanderbilt University School of Medicine. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center) ;
Chanock, Stephen (Centro Nacional de Investigaciones Oncológicas) ;
Easton, Douglas F (University of Cambridge. Centre for Cancer Genetic Epidemiology) ;
Wolpin, Brian M. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Stolzenberg-Solomon, Rachael Z. (Centro Nacional de Investigaciones Oncológicas) ;
Klein, Alison P. (Johns Hopkins School of Medicine. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center) ;
Amundadottir, Laufey T. (National Cancer Institute (Bethesda, Estats Units d'Amèrica)) ;
Marti-Renom, Marc A. (Universitat Pompeu Fabra. Centre de Regulació Genòmica (CRG-UPF)) ;
Real, Francisco X (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ;
Malats, Núria (Centro de Investigación Biomédica en Red de Cáncer)
Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4. [...]
2021 - 10.1186/s13073-020-00816-4
Genome Medicine, Vol. 13 (february 2021)
|
|
|
4.
|
|
13 p, 2.1 MB |
Increased plasma levels of galectin-1 in pancreatic cancer : potential use as biomarker
/
Martinez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Barranco, Luis E. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Orozco, Carlos A. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Moreno, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Oldfield, Lucy (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Neoptolemos, John P. (Department of General Surgery, University of Heidelberg, Heidelberg, Germany) ;
Greenhalf, William (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Earl, Julie (Hospital Universitario Ramón y Cajal (Madrid)) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Costello, Eithne (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Navarro, Pilar (Institut d'Investigació Biomèdica Sant Pau)
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. [...]
2018 - 10.18632/oncotarget.26034
Oncotarget, Vol. 9 (august 2018) , p. 32984-32996
|
|
|
5.
|
|
15 p, 4.2 MB |
Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1
/
Herrera, Alberto (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Herrera, Mercedes (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Guerra-Perez, Natalia (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Galindo-Pumariño, Cristina (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Larriba, María Jesús (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
García-Barberán, Vanesa (Hospital Clínico San Carlos (Madrid)) ;
Gil, Beatriz (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Giménez-Moyano, Sara (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Ferreiro-Monteagudo, Reyes (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Veguillas, Pilar (Hospital Universitario de Guadalajara) ;
Candia, Antonio (Hospital Universitario de Guadalajara) ;
Peña, Raúl (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Pinto, Jesús (Hospital Virgen de la Concha (Zamora)) ;
García-Bermejo, Mª Laura (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Munoz, Alberto (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Garcia de Herreros, Antonio (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bonilla, Félix (Centro de Estudios Biosanitarios, Madrid, Spain) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Peña, Cristina (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Universitat Autònoma de Barcelona
Carcinomas, such as colon cancer, initiate their invasion by rescuing the innate plasticity of both epithelial cells and stromal cells. Although Snail is a transcriptional factor involved in the Epithelial-Mesenchymal Transition, in recent years, many studies have also identified the major role of Snail in the activation of Cancer-Associated Fibroblast (CAF) cells and the remodeling of the extracellular matrix. [...]
2018 - 10.1038/s41389-018-0085-z
Oncogenesis, Vol. 7 (september 2018)
|
|
|
6.
|
|
6 p, 374.8 KB |
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Valladares-Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ;
Bando, Inmaculada (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Safont, Maria Jose (Hospital General Universitario de Valencia) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Arrivi, Antonio (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conde, Verónica (Hospital Universitario Virgen de las Nieves (Granada)) ;
Ortiz, Maria José (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Alonso, Beatriz (Hospital Universitario de Canarias (La Laguna)) ;
Ruiz de Mena, Inmaculada (Spanish Cooperative Group for the Treatment of Digestive Tumours) ;
Díaz-Rubio, Eduardo (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Universitat Autònoma de Barcelona
Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patients. [...]
2019 - 10.1038/s41416-019-0537-z
British Journal of Cancer, Vol. 121 (july 2019) , p. 378-383
|
|
|
7.
|
|
12 p, 744.6 KB |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
/
Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Safont, María José (Hospital General Universitario de Valencia) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
García-Paredes, Beatriz (Hospital Clínico San Carlos (Madrid)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Dueñas, Rosario (Complejo Hospitalario de Jaén) ;
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Losa, Ferrán (Hospital General de l'Hospitalet) ;
Valladares Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ;
González, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ;
Aranda Aguilar, Enrique (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ;
Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202
|
|
|
8.
|
|
9 p, 1023.2 KB |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial
/
Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ;
Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Cervantes, Andrés (Universitat de València) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Mizuguchi, Hirokazu (Taiho Oncology) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235
|
|
|
9.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
